Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer
- Published on 03/28/2024
- Reading time: 4 min.
Kanchi Patell a , Veronica Lee Mears b , Michael H. Storandt c & Amit Mahipal d,*
a Hematology and Oncology Fellow, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA
b GI Oncology Clinical Pharmacist Specialist, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA
c Internal Medicine Resident, Mayo Clinic, Rochester, MN, USA
d University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA
CONTACT Amit Mahipal mailto:amit.mahipal@uhhospitals.org Seidman Cancer Center, Case Western reserve university, 11100 Euclid Avenue, Cleveland, OH 44106, USA
Abstract
Introduction Colorectal cancer (CRC) is the third most diagnosed cancer globally and despite therapeutic strides, the prognosis for patients with metastatic disease (mCRC) remains poor. Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) targeting VEGFR −1, −2, and −3, and has recently received approval by the U.S. Food and Drug Administration for treatment of mCRC refractory to standard chemotherapy,...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
